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ABSTRACT ABSTRACT
P
rions cause fatal and transmissible neurodegenerative
disease. These etiological infectious agents are formed
in greater part from a misfolded cell-surface protein
called PrP
C. Several mammalian species are affected by the
diseases, and in the case of ‘‘mad cow disease’’ (BSE) the agent
has a tropism for humans, with negative consequences for
agribusiness and public health. Unfortunately, the known
universe of prion diseases is expanding. At least four novel
prion diseases—including human diseases variant
Creutzfeldt-Jakob disease (vCJD) and sporadic fatal insomnia
(sFI), bovine amyloidotic spongiform encephalopathy (BASE),
and Nor98 of sheep—have been identiﬁed in the last ten
years, and chronic wasting disease (CWD) of North American
deer (Odocoileus Specis) and Rocky Mountain elk (Cervus elaphus
nelsoni) is undergoing a dramatic spread across North
America. While ampliﬁcation (BSE) and dissemination (CWD,
commercial sourcing of cervids from the wild and movement
of farmed elk) can be attributed to human activity, the origins
of emergent prion diseases cannot always be laid at the door
of humankind. Instead, the continued appearance of new
outbreaks in the form of ‘‘sporadic’’ disease may be an
inevitable outcome in a situation where the replicating
pathogen is host-encoded.
Prion Diseases and Prion Proteins
Prion diseases, sometimes referred to as transmissible
spongiform encephalopathies (TSE), affect a variety of
mammals. These neurodegenerative diseases are incurable,
with pathogenesis in the central nervous system leading slowly
but inexorably to death. These diseases are exempliﬁed in
humans by Creutzfeldt-Jakob disease (CJD), while in cattle the
head-line grabbing ‘‘mad cow’’ disease, bovine spongiform
encephalopathy (BSE), immediately comes to mind. A
remarkable feature of this class of diseases is the extended
period of time between exposure to the infectious agent and
manifestation of clinical symptoms. This period may typically
be reckoned in decades for the syndromes in humans, but can
be as short as 1.5 years in the case of iatrogenic disease [1]. In
laboratory rodent models this period is usually less than one
year. Although once attributed to hypothetical
unconventional viruses, evidence has accumulated that these
pathogensinvolveafundamentallydifferenttypeofreplicative
process—epigenetic templated protein misfolding—a process
with some similarity to pathogenic events in several other
(albeit nontransmissible) neurodegenerative diseases such as
Parkinson disease and Alzheimer disease.
The infectious agent in prion diseases is believed to be
composed of a single protein and, not surprisingly, this is
dubbed the prion protein (PrP). The prion hypothesis states
that a disease-associated and improperly folded form of PrP
(generally termed PrP
Sc) is derived from a benign membrane-
displayed precursor protein, PrP
C, encoded on Chromosome
2 and Chromosome 20 in mice and humans, respectively [2].
The epidemiological appearance of certain human prion
diseases in genetic and sporadic forms (not the case with
other classes of infectious pathogens) is also compatible with
the concept of aberrant metabolism of a ‘‘host’’ cellular
component. Indeed, a tri-modal epidemiological
manifestation is a unique feature of prion diseases and
unique in the realm of medical biology, blurring the dividing
lines between metabolic and infectious diseases. In the case of
inherited prion diseases such as familial CJD (now referred to
as genetic CJD), vertical transmission is not by an infectious
route but by germ-line inheritance of a mutated form of the
prion protein. Here the mutations may lead to misfolding by
encouraging the overrepresentation of transient folding
intermediates [3]. Several examples are now known, and these
have been reviewed elsewhere [4]. Sporadic prion disease is
arguably the most fascinating and unpredictable
epidemiological manifestation of all, and the curious
mechanisms by which this might arise are discussed later. The
best-documented sporadic disease is sporadic CJD (sCJD).
This comes in several subvarieties, and it is known that a
common asymptomatic polymorphism in the human PRNP
coding region, either a methionine or a valine at codon 129,
has a profound effect upon the appearance of this disease (an
important modulatory role of this polymorphism is also
apparent for genetic prion diseases such as genetic CJD
(gCJD)). With regard to infectious disease manifestation, BSE
is the best-known example. In this disease, infectivity is
acquired by an oral route of administration. Exposure to BSE
prions in Europe has lead to about 170 cases of variant CJD
(vCJD) thus far.
From PrP
C to PrP
Sc
PrP
C is synthesized in the secretory pathway, and the
mature form of mouse PrP
C is a 210 amino acid protein, N-
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glycosylphosphatidylinositol anchor. The structure of PrP
C
consists of two domains: an N-terminal ﬂexibly disordered
domain which is capable of binding copper, and a C-terminal
a-helical domain [5,6]. In contrast, PrP
Sc is enriched in b-
sheet content and is characterized by its poor solubility in
nondenaturing detergents, propensity for aggregation, and
partial resistance to proteinase K (PK) digestion [7] (Figure 1).
Digestion of PrP
Sc with PK results in an N-terminally
truncated fragment originally called PrP27–30 in the case of
scrapie infections and more generally termed PrP
res,t o
denote protease-resistance in vitro. Although PrP
Sc appears
to be more thermodynamically stable than PrP
C, folding of N-
terminally truncated recombinant PrP
C to the a-helical
conformation takes place with rapid kinetics at neutral pH
[8]. Since a substantial energy barrier exists between a-helical
PrP
C and isoforms rich in b-structures [9], the resulting
‘‘kinetic trap’’ for nascent PrP
C synthesized at neutral pH
overwhelmingly favors formation of the a-helical
conformation, perhaps consistent with the observation that
spontaneous formation of PrP
Sc (e.g., de novo genesis of
sporadic disease such as sCJD, as discussed below) is not
favored under physiological conditions. Although there is
debate as to whether other proteins or accessory molecules
participate in the refolding event in vivo [10–12], PrP
C is
absolutely required for the disease process insofar as PrP
knockout mice fail to develop disease when inoculated with
prions [13].
Prion Strains and Host Range
As replicating pathogens, prions do have two attributes
that seem ‘‘viral-like.’’ The ﬁrst is that they can exist in
strains, that is to say, isolates appear to have distinctive
phenotypic attributes within the same genotype of host
(typically a mouse inbred strain). These attributes may
include incubation time from inoculation to disease onset,
neuropathology, the degree of N-glycosylation of PrP
Sc, and
the degree of resistance to proteinase K digestion in vitro. In
a molecular sense, prion strains are thought to correspond to
conformational subvarieties of PrP
Sc that are capable of
accurately templating this three-dimensional information to
nascent PrP
Sc molecules [14–17].
Prions are also like viruses in that they have host-range
phenomena. They can adapt to certain host species and
conversely, may falter (or at least be impeded) when
introduced into a different species [18,19]. In an
experimental setting two variables may be important for
abrogating species barriers to ‘‘foreign’’ prions. The ﬁrst is to
match the primary sequence of the host PrP
C to the primary
sequence of the PrP
Sc polypeptides in the inoculum of
interest, ﬁrst done for hamster prions by transgenetic means
[20,21]. A second operational variable is to remove an
interfering effect of the endogenous (typically mouse) PrP
C
allele upon assay of heterologous prions, and this is
accomplished by using a gene-ablated (Prnp
0/0) genetic
background for the prion-inoculated animals [13,22]. These
parameters still cannot be the whole story, though, as
evidenced by the case of the bank vole, which—in spite of
having PrP with seemingly unremarkable primary structure—
is susceptible to prions from a number of mammals [23].
DOI: 10.1371/journal.ppat.0020026.g001
Figure 1. Formation of PrP
Sc and Pathways to Disease
(A–C) Structures of PrP
C and PrP
Sc.
(A) NMR structure of PrP
C with a notional addition of the N-terminal
region (which is unstructured in NMR analyses). Copper ions (turquoise
spheres) and coordinating side chains (dark blue) are shown. Note that
the C-terminal globular domain has two short beta strands (turquoise
arrows) and three a-helices (red; image courtesy of Glenn Millhauser,
University of California Santa Cruz).
(B) A structure for PrP
Sc deduced from electron microscopic analyses of
purified material. The background represents the two-dimensional
crystals of PrP27–30 after image processing and the foreground a
notional structure for PrP
Sc with the central region of the protein
rearranged into triangular stacked b-helices (image courtesy of Cedric
Govaerts and Holger Wille, University of California San Francisco).
(C) Linear representation of PrP
C and PrP
Sc, and N-terminal truncation of
PrP
Sc by proteinase K, to create PrP27–30. For illustrative purposes the
conformational change in the centre of the molecule is shown by an
altered color for helix A. Also note that other conformational changes
may occur C-terminal to this position, but have been omitted for the
sake of clarity.
(D) Pathways to disease. In prion infections, conversion of PrP
C to PrP
Sc is
initiated by a pre-existing seed of PrP
Sc. In genetic diseases the mutant
form of PrPC denoted PrPM may misfold and aggregate, and in some case
acquire PrP
Sc-like properties sufficient to initiate disease in inoculated
recipient animals. In sporadic disease the mechanism of spontaneous
misfolding to PrP
Sc is unknown.
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replication that has no precise equivalent in the events that
might typically preoccupy mammalian virologists, namely
synthesis of the genome-length nucleic acids, synthesis of
viral proteins required for propagation, and virion
interactions with cell-surface receptors. Also, as may be
appreciated, the distinction between ‘‘non-host’’ extrinsic
chemistry and intrinsic physiological events is more slender
in prion disease than for viral infections: in the latter case the
infectious particle may be composed of many varieties of
macromolecules and the molecular weight may rank in the
millions. The proximity of prion protein misfolding and
replication to normal cellular events can present unique
challenges for diagnosis, and current procedures warrant
description before tackling the mysteries of prion biogenesis
and emerging diseases.
Prion Gazing
Static diagnostics. Several techniques are used for
postmortem diagnosis of prion disease [24] (Table 1). Brains of
infected individuals usually exhibit pronounced spongiform
change (areas of vacuolation), neuronal degeneration and
death, astrogliosis, and occasionally, the accumulation of
amyloid plaques containing aberrant PrP. Spongiform change
can be observed using standard histological procedures, and
abnormal PrP deposits can be viewed following pretreatment
with formic acid and hydrated or hydrolytic autoclaving [25],
to reduce the immunoreactivity of PrP
C, prior to staining with
a PrP-speciﬁc antibody (see Figure 2). Other diagnostic tests
rely on the detection of PrP
res as a surrogate marker for PrP
Sc.
Following PK treatment, PrP
res can be detected using either a
Western blot or an ELISA, with these strategies forming the
basis for two of the most widely used commercial tests for BSE
(from Prionics, Schlieren, Switzerland, and BioRad, Hercules,
California, United States, respectively). A distinct approach,
one that circumvents protease digestion, is the conformation-
dependent immunoassay [16,26,27]. This method takes
advantage of the differential availability of sequestered
antibody epitopes between PrP
C and PrP
Sc. An antibody is
used which recognizes a central epitope with differential
accessibility between PrP
C (available) and PrP
Sc (not accessible
until thermal or chemical denaturation). Ratios are calculated
between signals obtained by ELISA for the native and
denatured forms of the test samples, which are then used to
ascertain the presence of PrP
Sc. In this technique there is the
potential to detect soluble forms of PrP
Sc which may
outnumber their insoluble and more protease-resistant
counterparts. Lastly, antibodies have now been described
which may react with determinants unique to PrP
Sc [28–31].
Active diagnostics. In contrast to static diagnostics which
biochemically detect aberrant PrP, active diagnostics amplify
PrP
Sc or infectivity in vivo or in vitro before a detection step
or biological readout. The prion bioassay in mice is the most
commonly used method for assaying infectivity in vivo.
Following intracerebral inoculation of the test sample, mice
typically succumb to prion disease following an incubation
Table 1. Commonly Used Methods for Detecting TSE and PrP
Sc
Method Principle Notes Reference(s)
Histology/immunohistochemistry
a Fixed tissue is examined for the hallmarks of
prion disease or processed by hydrated or
hydrolytic autoclaving followed by
immunodetection of aberrant PrP deposits
Gold standard for confirming prion disease
diagnosis; neuroanatomical lesions are
characteristic of individual prion strains
Reviewed in [23,93]
Western blot/ELISA
a Homogenate is digested with PK to remove PrP
C
followed by immunodetection of PrP
Sc using either
Western blot or ELISA formats
Basis for many commercially available tests
for TSE; rapid method
Reviewed in [23,93]
Conformation-dependent
immunoassay
An antibody which recognizes a central epitope
with differential accessibility between PrP
C (available)
and PrP
Sc (not accessible until denaturation) is used
in a sandwich ELISA format. Ratios calculated between
signals obtained for the native and denatured forms
of the test sample signify the presence or absence
of PrP
Sc
No protease digestion is required; capable of
detecting soluble and more protease-sensitive
forms of PrP
Sc; rapid method
[16,26,27]
Bioassay (wild-type mice) Test samples are injected intracerebrally into mice and
disease progression is monitored
Subject to species barrier effects (inefficient
transmission or extended incubation times);
expensive, time-consuming, and labour-intensive
[94]
Bioassay (transgenic
indicator mice)
Transgenic mice expressing the PrP gene of interest
(on a mouse PrP
0/0 background) are inoculated as above
Eliminates species barrier effects, resulting in
shorter incubation times
[32–35]
Scrapie cell assay Highly prion-susceptible N2a cells are exposed to the
test sample, split three times, filtered onto an ELISPOT
plate, digested with PK, and then stained for PrP
Sc.
Positive cells are counted using a specialized computer
setup
Can quantitate levels of infectivity; 103 faster than
mouse bioassay and more than two orders of
magnitude less expensive
[36]
PMCA An excess of PrP
C and repeated cycles of amplification
and sonication are used to amplify any PrP
Sc present
in the test sample
Can detect PrP
Sc in pre-clinical (asymptomatic)
infected animals; can detect PrP
Sc in the blood of
experimentally infected hamsters; amplified PrP
res
is infectious to hamsters
[37,95–97]
‘‘Active’’ assay methods are italicized.
aAlternative histochemical techniques and/or immunoprecipitations with antibodies with differential selectivity for PrP
C and PrP
Sc have also been described (see main text).
DOI: 10.1371/journal.ppat.0020026.t001
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strain of mouse and prion strain utilized). Although
considered to be the gold standard, this bioassay system has a
number of important drawbacks. Firstly, bioassays are
expensive, labour intensive, and time-consuming. Second,
unless mouse or rodent-adapted prions are being tested, these
bioassays may be subject to species–barrier effects leading to
prolonged incubation times or inefﬁcient transmission of
disease. Attempts to circumvent the species barrier have
resulted in the development of transgenic indicator mice,
mice which express PrP
C of the same amino acid sequence as
the PrP
Sc in the test inoculum [12,32–35]. As mentioned, wild-
type bank voles have an unexpected susceptibility to prion
disease and these may prove versatile as a miner’s canary for
emergent diseases of unknown tropism.
Although invaluable, mouse bioassays are not high
throughput. Another active technique, which is ten times
faster than conventional bioassays and approximately two
orders of magnitude cheaper, is the scrapie cell assay [36].
This cell culture-based method utilizes sublines of mouse N2a
neuroblastoma cells that have been selected for enriched
susceptibility to prions and measures the ability of a test
sample to generate PrP
Sc-positive cells. Following exposure,
cells are split three times (to remove any PrP
Sc left over from
the test sample), ﬁltered onto the membrane of an enzyme-
linked immunospot (ELISPOT) plate, digested with PK, and
immunostained for PrP. Quantitation is performed using an
ELISPOT system (a stereo microscope equipped with a
camera and scanner linked to specialized software) and
comparison to standard curves generated from titred samples
results in a measure of the infectivity of the test sample.
Greater sensitivity can be obtained if the scrapie cell assay is
performed in endpoint titration format. One drawback of
this technique is that attempts to use mouse-adapted prions
other than the Rocky Mountain Lab isolate (such as the
murine Me7 and 22A isolates) were unsuccessful [36].
A third active diagnostic technique, denoted PMCA
(protein misfolding cyclic ampliﬁcation), was developed by
Soto and co-workers as a means of producing large
quantities of PrP
res in vitro [37] (Figure 3). The method is
loosely similar in a conceptual sense to nucleic acid PCR.
Fresh brain homogenate from non-infected animals is used
as a source of PrP
C, and brain homogenate from scrapie-
infected animals as a source of PrP
Sc [38]. In this analogy,
PrP
Sc is akin to the rare nucleic acid target sequence of PCR,
and PrP
C is akin to the cocktail of oligonucleotide primers
and mononucleotides that allow de novo nucleic acid
synthesis. Small amounts of infected material are diluted into
normal brain homogenate and in vitro conversion—
presumably a form of templated protein refolding—is
allowed to proceed at 37 8C. A key ingredient is a subsequent
sonication step, formally analogous to thermal denaturation
of complementary DNA strands in a PCR reaction. Here,
mechanical energy is used to break up newly formed PrP
aggregates into smaller structures, with the latter providing
new seeds for PrP
res formation in reiterations of the two-step
procedure. In this way repeated cycles of conversion and
sonication are performed in order to amplify any PrP
Sc
present in the starting sample. Conversely, only modest
amounts of PrP
res are generated if the sonication step is
omitted [37,39,40].
The Expanding Universe of Prion Diseases
vCJD and ‘‘mock sCJD’’ in humans. Suitably equipped with
diagnostic savvy we may now move to emergent prion
DOI: 10.1371/journal.ppat.0020026.g002
Figure 2. Pathology in CWD-Infected Animals
(A) Histologic lesions of CWD in the dorsal motor nuclei of the vagus nerve within the medulla oblongata of a CWD-affected elk. Note spongiform
change, intraneuronal vacuoles, and mild gliosis (hematoxylin and eosin stain, 1003 magnification).
(B) PrP amyloid deposit stained by immunohistochemistry (brown) and surrounded by vacuoles (original magnification 1803).
(C) Perineuronal and extracellular deposits of abnormal PrP (PrP
CWD, analogous to PrP
Sc) in a CWD-affected mule deer (original magnification1803).
(D) PrP
CWD deposits in the germinal centres of lymphoid follicles in the tonsils of a mule deer (immunohistochemistry, original magnification 503).
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diseases deﬁned in the last ten years, or as diseases that have
undergone a dramatic increase within the same time period.
The ﬁrst example, vCJD, was ﬁrst recognized in 1996, and the
occurrence of this disease as a consequence of the UK BSE
epidemic has been described in detail elsewhere [41,42].
While large-scale screening programs of diverse livestock and
cervid species prompted in greater part by the vCJD epidemic
have increased the spectrum of prion diseases, surprises have
also emerged in the context of the human disease. All
clinically conﬁrmed cases of vCJD have been of the codon 129
M/M genotype, and the one ‘‘case’’ of vCJD that has been
sighted in a non-M/M genotype occurred in the form of an
asymptomatic M/V heterozygote patient who received a blood
transfusion from a vCJD donor [43]. This suggests that
infections are proceeding at a slower pace in M/V and V/V
individuals in the UK exposed to BSE prions, and that these
individuals currently have subclinical disease. In agreement
with these ideas, transgenic mice expressing just the human
129V form of PrP
C exhibit a signiﬁcant barrier to infection
with either BSE or vCJD prions, and those that do become
infected have distinct neuropathological characteristics and
propagate a different type of PrP
Sc from vCJD [44]. As
expected, the majority of mice expressing human 129M PrP
C
DOI: 10.1371/journal.ppat.0020026.g003
Figure 3. Schematic Representation of the PMCA Procedure
Brain homogenate from an infected animal (containing PrP
Sc) is diluted into homogenate from a healthy animal (containing PrP
C) and incubated at 37
8C. During this stage, some molecules of PrP
C are converted to PrP
res and are added to the growing PrP
res unit. Sonication breaks up PrP
res into smaller
units, generating new seeds for conversion. These steps are repeated in a cyclic fashion in order to amplify the amount of PrP
res present in the initial
sample. The stoichiometry and directionality of amplification depicted are for illustrative purposes only and are not meant to represent intrinsic
properties of the system.
PLoS Pathogens | www.plospathogens.org March 2006 | Volume 2 | Issue 3 | e26 0156display the hallmarks of vCJD upon inoculation with BSE or
vCJD prions, with one remarkable exception. A single mouse
inoculated with BSE prions developed a disease
indistinguishable from human sporadic CJD [33]. This result
has led to the suggestion that a sliver of sCJD cases in Europe
may have resulted from BSE exposure (i.e., are vCJD cases
masquerading as sCJD), but since the ‘‘mock’’ sCJD resulting
from oral exposure to BSE prions has the hallmarks of
conventional sCJD type, establishing this inference will be
tricky. In Switzerland, a country with documented cases of
BSE, the incidence of sCJD underwent a 2-fold increase in
2001 [45]. However, a large-scale epidemiological study failed
to ﬁnd any changes in the characteristics of sCJD in the UK
[46].
sFI in humans. Whereas fatal familial insomnia is a genetic
disease caused by a PRNP D178N mutation in cis to a
methionine polymorphism at codon 129, more recent work
has described a sporadic version of the same syndrome. To
date, eight cases of sporadic fatal insomnia (sFI) have been
reported [47–50], all of which resemble typical fatal familial
insomnia and are homozygous for the methionine codon 129
polymorphism but lack any mutation in the PRNP gene. sFI
has successfully been transmitted to mice and the resulting
neuropathology and electrophoretic signature of PrP
Sc are
indistinguishable from those obtained with mice inoculated
with fatal familial insomnia isolates.
BASE in cattle. Here, abnormal presentation of prion
disease in two cattle in Italy was sufﬁciently distinct from BSE
as to suggest a distinct neurological syndrome denoted
bovine amyloidotic spongiform encephalopathy (BASE) [51].
Notable amongst the histopathogical features were
deposition of amyloid plaques in the thalamus, subcortical
white matter, and the olfactory bulb, while PrP
Sc detected by
Western blotting did not have the preponderance of di-
glycosylated PrP forms typical of BSE. Instead, the signature
from this kind of analysis was most akin to that of type M/V2
sCJD (a subtype of sCJD characterized by Kuru-like plaques
and so-called type 2 PrP
Sc). Perhaps this may be related to
observation that upon inoculation of ‘‘humanized’’ mice with
BSE prions, a small group of mice propagated a prion with
similarities to sCJD (see above) [33]. Results from BASE serial
transmission experiments (to prove that BASE results from
an infectious TSE agent) have not yet been published.
Nor98 in sheep. A fourth emergent disease, sometimes
referred to as atypical scrapie, was ﬁrst detected in Norwegian
sheep eight years ago [52]. There was no evidence of lateral or
horizontal transmission, with cases (one per ﬂock) observed in
geographically dispersed locations. Furthermore, the novelty of
this disease extended beyond these epidemiological
observations to include distinctive genetic, biochemical, and
histopathological signatures. These correspond to occurrence
in supposedly scrapie-resistant ovine Prnp genotypes [53,54],
proteaseresistantPrPofanunusuallyshorttype(;12kDa)[52],
and immunohistochemical detection of PrP
Sc deposition in the
cerebellar cortex yet no obvious deposition in the medulla
oblongata, which is the primary and earliest site of detection in
classical scrapie. Thus far, PrP
Sc has not been found in the
lymphoreticular system. Subsequent analyses have identiﬁed
Table 2. Emerging Prion Diseases in Animals and in Humans
Disease (Host) Geographical Location
of First Sighting
Satellite Sightings Notable Features Experimental
Transmission?
Country Year Countries Year
vCJD (in humans) UK 1996 [98] France
Italy
Ireland
Canada
US
Spain
Netherlands
1996 [99]
2002 [100]
1999 [101]
2002 [102]
2002
2005
2005
Much shorter incubation
period than sporadic CJD;
presence of florid plaques;
may be transmissible
by blood transfusion [42,102]
Yes—to mice [103] and
transgenic mice expressing
human PrP [32]
sFI (in humans) US 1999 [47,48] South Africa
Japan
2000 [49]
2005 [50]
Clinically resembles the familial
version of the disease but the
PRNP D178N mutation is absent;
all patients have been homozygous
for methionine at codon 129
Yes—to transgenic mice
expressing chimeric
human/mouse PrP [48]
CWD (in mule deer,
white-tailed deer, and elk)
US 1967 [105] Canada
(see Figure 4)
1996 [67] Ease of horizontal transmission of
infectivity and rapid spread of the disease
Yes—to ferrets [106],
squirrel monkeys [107],
and transgenic mice
expressing cervid PrP
[35,108]
BASE (in cattle) Italy 2004 [51] None None Presence of PrP-positive amyloid plaques
[51]; different neuroanatomical distribution
of PrP
Sc than for BSE; PrP
res electrophoretic
signature is more reminiscent of sporadic
CJD type M/V2 than of typical BSE
Unknown
Nor98 and atypical
scrapie (in sheep)
Norway 1998 [52] Germany
France
Sweden
Portugal
Belgium
2004 [55]
2004 [55]
2004 [56]
2004 [53]
2004 [57]
Sheep with the PrP
ARR allele are susceptible
[53,54]; distinct neuroanatomical distribution
of PrP
Sc and histopathological features from
scrapie [52]; low MW PrP
res band around 12
kDa [52]; no PrP
Sc in the lymphoid tissue [52]
Yes—to transgenic mice
expressing the ovine
PrP
VRQ allele [109]
DOI: 10.1371/journal.ppat.0020026.t002
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Germany, Sweden, Portugal, and Belgium [53,55–57].
From the foregoing data, it is unclear whether labeling
Nor98 as a type of scrapie is accurate, or is more of a reﬂexive
actionmade onthe basisofthe hostspecies. Irrespectiveof the
wisdom of this label, a further twist in the story is that Nor98
has now been shown to be transmissible. Transmission of
either Nor98 (Norwegian isolate) or discordant (atypical)
scrapie cases (French isolates) to ovinized mice expressing the
PrP
VRQallelefaithfullyrecapitulatedthediseaseseeninsheep,
highlighted by the presence of the ;12-kDa PrP
res band and
the lack of deposition in lymphoid tissue. The remarkable
similarities between Nor98 and the discordant scrapie cases
followingtransmission suggestthattheTSEagentsresponsible
for disease represent either a single strain or two closely
related strains. Alternatively, Nor98 may represent a sporadic
prion disease, albeit one not exactly akin to sCJD [52]. The
short protease-resistant fragments seen in Nor98 seem more
reminiscent,ifanything,ofcertainformsofthehumangenetic
prion disease GSS [58,59], although N-terminal sequencing of
these fragments is awaited to validate or refute this mooted
relationship.
CWD in deer and elk. CWD is no newcomer, being
recognized as far back as 1967 as a clinical syndrome of
unknown etiology. The histopathological and biochemical
characteristics have been described in detail [60] and fall
within the mainstream of prion diseases. These are illustrated
in Figure 2. However, CWD possesses two striking features
that warrant our attention. First, it is the only prion disease
known to affect free-ranging mule deer, white-tailed deer,
and Rocky mountain elk. Second, it is a disease where
horizontal spread is readily recognizable [61,62]. With the
possible exception of natural scrapie, this stands in contrast
to other important prion diseases where horizontal
transmission happens by virtue of human activity (e.g., by
iatrogenic procedures or industrial cannibalism [63–65]).
Likely related to the second point, CWD can attain
spectacular ‘‘attack rates’’ in affected populations
DOI: 10.1371/journal.ppat.0020026.g004
Figure 4. CWD in North America
Geographical distribution in North America (A), and in expanded view of Alberta and Saskatchewan (B). Data in (A) is correct as of February, 2006, and
reproduced with kind permission of the CWD Alliance.
In (A), states or provinces where CWD has been diagnosed in captive populations are cross-hatched. CWD diagnosis in free-ranging animals is indicated
by red circles.
In (B), CWD diagnosis in free-ranging animals is indicated by red circles and in farmed animals with green circles.
(C) Mule deer with clinical CWD showing emaciation and loss of body condition (photo courtesy of T. R. Spraker).
(D) Elk with clinical CWD showing emaciation and excessive salivation (photo courtesy of E. S. Williams).
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essentially 100% in captive research facilities [60]), and is
undergoing a swift geographical spread across North
America. It is in the context of its almost wildﬁre spread that
CWD is considered an emergent threat (Figure 4). Insofar as
moose can be affected (http://www.cwd-info.org), the
prospects for colonization of new species in the tundra and
boreal forest are truly worrying.
Some aspects of CWD epidemiology are puzzling. As noted,
there are two types of affected populations, corresponding to
feral and farmed cervids. Insofar as incidences in the two types
of populations are both on the rise, they are referred to as
epidemics. In the case of free-ranging cervids, an epicenter is
located in the contiguous parts of the northeast corner of
Colorado, southeast Wyoming, and the extreme southwest
corner of Nebraska. Additional cases have been reported in
other Rocky Mountain and Great Plains states, as well as more
surprising instances in noncontiguous states such as Illinois
and Wisconsin (Figure 4). For farmed cervids, instances have
been reported in Colorado, Kansas, Oklahoma, Minnesota,
Nebraska, South Dakota, Wisconsin, and Wyoming.
Appearance in two populations is also the case in Canada
(albeit in smaller numbers), where there are four foci of free-
ranging animals in the province of Saskatchewan and one
focus in Alberta, and incidences in farmed animals in both
provinces. Geographic dispersion in farmed animals is
attributed to sale and transport of affected individuals, and
predicting the future spread of CWD within the captive cervid
industry is problematic, as movements are commercially
based and unregulated in many states and provinces.
In any event, given the comparative ease with which
horizontalspreadcanbeobservedinanexperimentalsetting,a
causal connection can be posited between the two types of
epidemics, e.g., free-ranging infected animals came into
contactwithfarmedanimals,orviceversa.However,disparities
in geographic distribution have suggested this simple
explanation is inadequate [66]. Either the historic origin of a
putative point source goes back farther than suggested by
current records (with dispersion via migration or cryptic
vectorsintheyearspriortotheﬁrstrecognitionofthedisease),
or,there are CWD epidemics with etiologically distinct origins.
Forexample,isolatedpocketsofdiseasemayreﬂectthedenovo
emergence of sporadic CWD. Given the precedent of BSE, an
originfrom contaminated feedhastobe considered inthecase
of CWD in farmed cervids. In this instance though the
husbandry of these animals does not normally encompass
protein concentrate feed additives, and the prion strain of
CWD is distinct from BSE (itself rare in North America),
making this mechanism of disease spread unlikely.
Perhaps the greatest enigma in the case of CWD is how the
disease can spread horizontally. There are reported and
anecdotal instances where introduction of one affected
animal led to disease in several other members of a farmed
herd [67]. Also, physical proximity by penning is claimed to
increase disease incidence. An oral route of exposure is
inferred from the presence of infectivity in lymphoid tissue of
the alimentary canal [68,69], yet the problem remains as to
which bodily ﬂuid or secretion contains infectivity. Feces and
saliva are posited as being prion-contaminated, but a sighting
by way of a prion bioassay has yet to be made. Clearly,
deﬁnitive knowledge on this point is required for rational
control measures, yet there is a partial sense of de ´ja ` vu here
for earlier failures to identify the mechanism of spread in the
‘‘other’’ prion disease with putative horizontal spread, namely
natural scrapie of sheep and goats. Recent work has illustrated
the novel idea that chronic inﬂammation can modify the
organ tropism of prions [70], and that infectivity can be
detected in the urine of mice with chronic inﬂammatory
kidney disease [71] (albeit assayed by the ‘‘sensitive’’ route of
intracerebral inoculation rather than by an oral route that
may be more pertinent in vivo). Furthermore, deposits of
PrP
Sc have been found in the mammary glands of sheep with
coincident scrapie infection and mastitis [72]. These results
have led to the suggestion that inﬂammation mayplay a role in
the horizontal spread of prions.
Unclassiﬁed prion disease in cattle. Last but not least,
large-scale surveillance programs enacted within the
European Union and Japan have unearthed several atypical,
‘‘waste-basket’’ prion diseases of cattle with distinct
biochemical signatures from BSE. Three cases were identiﬁed
in France in which an atypical molecular signature was
observed (increased size of unglycosylated PrP
res and less
preponderance for di-glycosylated PrP
res) [73]. In addition,
one abnormal case was identiﬁed in Japan with a similar
decreased percentage of di-glycosylated PrP
res, but with a
faster mobility of the unglycosylated form [74]. The origins of
such cases are enigmatic, with suggestions including infection
of cattle with scrapie prions, strain evolution of BSE, or the
occurrence of sporadic prion disease in these animals [73].
More stars or better telescopes? Our ability to detect prion
diseases is superior to ten years ago, and part of the expansion
in the universe of prion diseases is undoubtedly due to large-
scale animal screening programs initiated in the wake of BSE.
Highly organized human CJD surveillance systems have also
made their mark. For CWD, a case can be made that the
disease is expanding in the simple sense of the number of
affected animals increasing with each passing year. Is this the
whole story though? Beyond incidence of cases, is the pan-
global diversity of disease types increasing on a yearly basis
too? For Nor98, if we are lucky, ‘‘look-backs’’ from archival
samples may help us to understand if this new disease is an
impostor (i.e., in existence prior to the 1990s). More generally
though, the prion hypothesis predicts de novo biogenesis
could take place spontaneously. It is possible that insights into
the larger question of continuously emerging foci of disease
may come ﬁrst from laboratory rather than from
epidemiological studies.
Deciphering Sporadic Prion Disease
As noted previously, prion diseases are unique within the
ﬁeld of microbiology in having a tripartite (i.e., infectious,
genetic, or sporadic) epidemiological manifestation. Perhaps
the closest that conventional viruses can approximate this
state of affairs would be in the case of retroviruses, where an
RNA genome is reverse-transcribed into a cDNA copy. Here,
vertical transmission of an infectious state can occur via
chromosomal integration of the cDNA copy (provirus) into
cells of the germ-line, with subsequent expression of the
provirus in somatic cells leading to production of infectious
virions. Nonetheless, a functional proviral genome can only
appear from a precursor. Thus proviruses cannot appear ‘‘out
of nowhere,’’ and retroviruses cannot recapitulate a sporadic
epidemiology. In contrast, sporadic epidemiology can be seen
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protein folding disorders. However, before probing deeper
into this enigmatic epidemiological manifestation, it is worth
considering an alternative attribution.
The possibility that some cases of classical sporadic CJD
might be caused by an infectious etiology (from BSE, or even
BASE-affected animals) begs the larger question as to whether
all sporadic prion disease can be accounted for in this
fashion, i.e., are attributable to infection by pre-existing
prions. This theory has a seeming advantage in its economy,
but is it tenable? In the case of natural prion diseases of
animals, close scrutiny and clinical assessment of large herds
of livestock is difﬁcult to achieve. On the other hand,
epidemiological surveillance and neurological scrutiny are
performed to higher levels in a medical setting, and so it is to
the human population we must turn to best address this issue.
Here the sporadic diseases comprise sCJD and sFI, with the
bulk of information being available for the former. For the
case of BSE as a causative factor, insofar as sCJD (i) predates
BSE by decades, (ii) occurs in industrialized countries
geographically removed from the UK, and (iii) occurs in
people who have never visited the UK; an origin for
mainstream sCJD from BSE prions can be absolutely
excluded. This leads back to earlier musings on the origin of
sCJD [75] where attempts were made to link the disease to the
animal reservoirs of disease known at the time, principally
scrapie in sheep. These studies were negative. More recent
analyses of sCJD epidemiology again stress the role of
multiple point source events [76]. From the perspective of an
infectious etiology, this requires one to invoke another
hypothetical prion disease agent—one that must be
widespread to account for the occurrence of sCJD in all
countries at a remarkably similar rate. We now know about
BASE and Nor98, but to ascribe them this property would be
more than premature. In the case of BASE it is not known if
this disease is even transmissible. Nor98, though deﬁnitely a
disease to watch, has a 12-kDa PrP
res signature that is (at least
in sheep) quite different from that seen in sCJD, making a
causal link unlikely. Therefore, in the absence of a widely
disseminated reservoir of human-tropic prions that may serve
to initiate infections, other mechanisms must be entertained
for the origin of sCJD.
The pre-existing infectivity hypothesis (for want of a better
label)alsorunsintoproblemswhenoneconsidersanimalprion
diseases. As we have seen, these may be perpetuated by
horizontal spread, but there is a conundrum with regard to
origin. Many labs study experimental scrapie in rodents, and
theseprionisolatesarederivedfromexposuretomaterialfrom
scrapie-infected sheep, but from whence did sheep themselves
acquire disease? When did the ﬁrst scrapied sheep fall from
physiological grace to succumb to this neurological disease?
(Historical records make it seem quite likely this disease goes
back to the 1700s in Europe, and it has been suggested based
uponcompositionofChinesecharacters thatscrapie existedin
Ancient China [77]). A similar question pertains to the ﬁrst
cases of BSE. Were these spontaneous or (leading back to the
same question) attributable to a variant form of scrapie in the
largeUKsheeppopulation?Thus,evenifweputasidetheother
problems, the pre-existing infectivity hypothesis ultimately has
to invoke a ﬁrst spontaneous de novo synthetic event. While
impossible in the realm of virology, because we know the prion
precursorprotein(i.e.,PrP
C)ishost-encoded,this typeofevent
does not pose an impasse for the prion hypothesis: it is more a
question of ‘‘how?’’ rather than ‘‘if.’’
The prion universe: Big Bang or repeated ‘‘singularities’’?
Spontaneous prion creation might have happened only once
in the Earth’s biosphere, a prion Big Bang, so to speak, with
all current prion isolates representing the diaspora of this
proto-prion. However, there are hints that de novo synthesis
events may have happened more than once. Instead of a Big
Bang, a perhaps better astrophysical analogy would be the
continuous birthing of different varieties of stars from
condensation of gas clouds.
The evidence that prions might ‘‘ignite’’ spontaneously—
that sporadic disease represents de novo prion synthesis at
dispersed points in space and time—is accruing slowly, and is
along the following lines. From an epidemiological point of
view, excluding the trivial case of spreading CWD in farmed
animals by trucking, prion diseases are scattered
geographically, and there is no evidence for a universally
dispersed yet cryptic prion disease able to cause sCJD on all
inhabited continents. sCJD itself has several subtypes and may
in turn be different from sFI, again incompatible with a
universal sporadic agent and perhaps suggestive of a more
stochastic process of biogenesis. Last, there are three types of
experiments where infectious prions were created in the lab.
In one case this was addressed by overexpression of a P101L
mutant PrP, followed by transmission to TgP101L (but
asymptomatic) indicator mice [78,79]. (Absence of
spontaneous disease in low-expresser mice bearing the P101L
mutation has been noted by several labs, see also [80,81]). In
the second case, there was production via inoculation of
TgP101L indicator mice with b-sheet conformation synthetic
peptides [82], and in the third case by deliberate misfolding of
pure recombinant PrP [83]. The experiment with
recombinant protein was artiﬁcial in that truncated
misfolded PrP was inoculated into transgenic mice
overexpressing a similarly truncated form of PrP
C, and the
‘‘speciﬁc infectivities’’ (ID50 units per mg of total protein)
may lie orders of magnitude below those of natural prions.
Nonetheless, a precedent may have been established. Just how
this all might happen in vivo is not clear, and some
possibilities are presented in Table 3. What is also growing
clearer, however, is that the ‘‘gap’’ between the properties of
cellular prion proteins and their prionized counterparts may
be narrower than once believed. Yeast have true-breeding
cytoplasmic traits due to protein misfolding (commonly
referred to as yeast prions), and there is a debate as to
whether the prionized version of the yeast host proteins serve
a physiological purpose [84–86]. In the sea-slug Aplysia, prion-
like states of the neuronal mRNA translation factor CPEB
have been posited as stable guardians of synaptic memory
[87]. PrP
C itself was once thought to be a conﬁrmed singleton,
a monomer adhering to an a-helical lifestyle, but it is now
known that Cu(II) binding induces conformational changes
[88,89] and that N-terminal PrP sequences modulate
oligomerization [90], so it is not an enormous stretch to
consider whether a version of PrP
C capable of templated
propagation/perpetuation of a b-sheet state might be present
in healthy individuals. In vitro, PrP
C is capable of refolding to
quasi-PrP
Sc-like, albeit non-infectious b-oligomeric forms
using chemical denaturation and acidiﬁcation [9,91], while
thermal denaturation and manipulation of detergent
conditions can lead to formation of PrP27–30 [92]. Further
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C’s behaviour and ways
to subvert this molecule in vitro (e.g., facilitate these
conformational transitions under kinder, gentler conditions)
is eagerly awaited.
Conclusion
While some recent prion crises may be man-made
(ampliﬁcation of BSE), and some emerging diseases may be
exacerbated by human actions (trucking of CWD-affected
deer), it is extremely unlikely that the origins of all emerging
prion disease can be blamed on Homo sapiens. Tackling the
larger questions—and enigmas—of prion biology will be
important if we are to deal with emerging prion diseases in a
pro-active rather than a reactive manner. Horizontal spread
may either occur directly between infected animals or involve
the intervention of an environmental reservoir, but to be
brought under control these processes will need to be
demystiﬁed and deﬁned in terms of explicit biochemical
entities. Sporadic prion diseases may emerge continuously
from molecular wear and tear of PrP
C (an abundant neuronal
protein), and we need to understand the ins and outs of this
process, too. Cell biological systems or transgenic systems to
gently abuse PrP
C are urgently needed to supplant the harsh
conditions currently used in vitro. New diagnostics should be
brought to bear upon questions raised by emergent diseases,
and here PMCA may be particularly adept because of
sensitivity and because the process may be modiﬁed to be
informative about in vivo replicative mechanisms.
Where will the next prion epidemics emerge? During the
height of the BSE epidemic, meat and bone meal was
exported from the UK to non-European countries, and the
sequelae of these actions may yet to be felt. If in vivo systems
for de novo biogenesis can be made robust, an inevitable
conclusion is that sporadic prion diseases can appear
anywhere on the planet where there are large populations of
livestock. As yet unscathed, continents in the Southern
hemisphere may be home for the epidemics of the 21st
century. Fortunately, in dealing with the problems of
emergent syndromes we may note that sporadic disease has
one shining virtue—it is extremely rare, with an incidence of
between one and two cases per 2 million head of population.
While we put great faith in human ingenuity to tease apart
the processes of prion replication, dissemination, and
biogenesis, this biological obstacle may be a crucial ally in
keeping the prion expansion within reasonable bounds.
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